UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults
National Heart Centre Singapore
1,200 participants
Apr 29, 2024
OBSERVATIONAL
Conditions
Summary
Cardiovascular disease (CVD) imposes significant mortality and morbidity worldwide. However, large gaps in our knowledge of CVD still exist. The clinical conundrum of the extremes of spectrums of CVD continues to baffle clinicians and researchers alike. These include patients without any major cardiovascular (CV) risk factors developing acute myocardial infarction (AMI) at a relatively young age (\<50-60 years old), while at the other end of the spectrum, there are also patients with multiple CV risk factors but with minor or no coronary artery disease. These suggest the presence of other factors that predispose these patients to AMI.Recent advancements in technology, especially in the field of genomics, metabolomics, and proteomics, have led to exciting developments in our understanding of the development and prevention of CVD and AMI. In this study, the investigators aim to identify novel gene variants associated with the onset of MI in relatively young patients with minimal standard CV risk factors such as diabetes, obesity, hypertension and hypercholesterolaemia.Through genomic, metabolomics and proteomics analyses, this may better improve our understanding of the development of CVD and AMI, potentially developing novel preventive measures to reduce the risk or delay the onset as well as tailoring management plans to improve treatment outcomes and reduce adverse events for the patients.
Eligibility
Inclusion Criteria7
- Adult >21 years old.
- Age ≤50 years old irrespective of the presence of CV risk factors* at the time of myocardial infarction OR Age 51-60 years old with no more than 2 CV risk factor* at the time of myocardial infarction, excluding diabetes mellitus
- Able to provide informed consent.
- Patients who are willing and able to comply with the study visit and procedures.
- Prior type 1 myocardial infarction with angiographically/CT documented significant stenosis of ≥50% in LM or ≥70% in major epicardial/branch vessel (e.g. LAD, LCX, RCA).
- Patients who are from the three main races (Chinese, Malay, Indian). Race is self-identified by patient.
- Hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoker
Exclusion Criteria4
- Known familial hypercholesterolaemia, known vasculitides, end-stage renal disease and congenital heart disease.
- Prior PAD and Stroke
- Female patients who are pregnant
- Patients who are non-Asian
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06698341